# VectivBio (stock symbol: VECT) Logo in transparent PNG and SVG formats

## VectivBio Logo large

### VectivBio Logo large Download PNG (32.58 KB)

![VectivBio Logo large Download PNG (32.58 KB)](/img/orig/VECT_BIG-6f7de8e3.png)

### VectivBio Logo large Download SVG (2.98 KB)

![VectivBio Logo large Download SVG (2.98 KB)](/img/orig/VECT_BIG-4f1c833f.svg)

## VectivBio Logo icon format

### VectivBio Logo icon format Download PNG (24.38 KB)

![VectivBio Logo icon format Download PNG (24.38 KB)](/img/orig/VECT-b5f3d32e.png)

### VectivBio Logo icon format Download SVG (1.13 KB)

![VectivBio Logo icon format Download SVG (1.13 KB)](/img/orig/VECT-76b67705.svg)

## VectivBio Logo large for dark backgrounds

### VectivBio Logo large for dark backgrounds Download PNG (32.26 KB)

![VectivBio Logo large for dark backgrounds Download PNG (32.26 KB)](/img/orig/VECT_BIG.D-dc0ddcba.png)

### VectivBio Logo large for dark backgrounds Download SVG (2.98 KB)

![VectivBio Logo large for dark backgrounds Download SVG (2.98 KB)](/img/orig/VECT_BIG.D-cc65e763.svg)

## About VectivBio

VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). The company was incorporated in 2019 and is headquartered in Basel, Switzerland.

1. Website domain: vectivbio.com
2. Marketcap: $0.70 Billion USD


## Categories
- [x] ðŸ‡¨ðŸ‡­ Switzerland
- [x] ðŸ’Š Pharmaceuticals
- [x] ðŸ§¬ Biotech
